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Abstract
Bisulfite sequencing measures absolute levels of DNA methylation at single-nucleotide resolution,
providing a robust platform for molecular diagnostics. Here, we optimize bisulfite sequencing for
genome-scale analysis of clinical samples. Specifically, we outline how restriction digestion
targets bisulfite sequencing to hotspots of epigenetic regulation; we show that 30ng of DNA are
sufficient for genome-scale analysis; we demonstrate that our protocol works well on formalin-
fixed, paraffin-embedded (FFPE) samples; and we describe a statistical method for assessing
significance of altered DNA methylation patterns.
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The role of DNA methylation in human diseases has sparked interest in genome-scale
methods for DNA methylation profiling1. Among an array of protocols for measuring DNA
methylation, bisulfite sequencing stands out for its ability to quantify the DNA methylation
status of essentially all non-repetitive regions in the genome at single-nucleotide resolution2.
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We recently developed reduced representation bisulfite sequencing (RRBS) as an accurate
yet cost-efficient method for genome-scale DNA methylation analysis3,4. Here, we show
that RRBS is highly appropriate for DNA methylation profiling of human disease cohorts,
and we address four obstacles that hamper epigenome mapping in clinical samples: (i) High
input DNA requirements. Methods such as MeDIP-seq5, MBD-seq6, Methyl-seq7 and
CHARM8 consume micrograms of genomic DNA, which is infeasible for many clinical
samples such as tumors obtained by laser capture microdissection or rare stem cell
populations. (ii) Inability to analyze FFPE samples. We are not aware of a genome-scale
method for DNA methylation mapping that works well on formalin-fixed, paraffin-
embedded (FFPE) clinical samples, rendering many of the best-annotated patient cohorts
inaccessible for epigenome studies. (iii) Incomplete bisulfite conversion. Whole-genome
bisulfite sequencing cannot use specific primers to enrich for fully converted DNA, such
that incomplete bisulfite conversion is likely to result in measurement artifacts. (iv) Lack of
data analysis tools. Few statistical methods or bioinformatic tools exist that would allow
sensitive detection of DNA methylation alterations that distinguish disease case and control
samples.
The RRBS protocol combines DNA digestion with a methylation-insensitive restriction
enzyme and size selection to select a reproducible subset of the genome3,4. This ‘reduced
representation’ is bisulfite-sequenced and its DNA methylation profile compared between
disease cases and control samples. To translate the RRBS protocol from mouse to human,
we initially performed in silico digestions, confirming that MspI digestion and a size
selection of 40 basepairs to 220 basepairs enriches for CpG islands and promoter regions
(data not shown). We tested this protocol on two fresh-frozen clinical samples, a colon
tumor and adjacent normal tissue from the same patient. A total of 8.7 and 5.3 million high-
quality aligned reads were obtained, yielding DNA methylation data for more than 1 million
unique CpGs (Table 1). Highly quantitative data with more than 25 individual CpG
measurements were obtained for 65% of core promoters, 50% of CpG islands and 17% of
putative regulatory elements (Fig. 1a). Furthermore, we observed coverage of a sizable
number of CpG island ‘shores’9, enhancers, exons, 3′ UTRs, and repetitive elements (see
http://rrbs-techdev.computational-epigenetics.org for details). This constitutes a slight
improvement compared to previously reported RRBS in mouse samples4.
For the analysis of clinical samples, three aspects of the RRBS protocol were specifically
optimized. First, we minimized the input DNA requirement to be able to process minimal
tissue samples and FACS-sorted cell populations (Fig. 1b). In two subsequent rounds of
optimization we reduced the amount of input DNA from 1 μg to 300 ng and from 100 ng to
30 ng (Table 1), observing Pearson correlation coefficients of 0.97 and 0.96, respectively,
calculated over all CpGs with at least 25-fold sequencing coverage. This analysis was
performed on DNA from mouse ES cells rather than on human material to minimize the
number of potential confounding factors. To confirm that the low-input protocol works well
for human disease samples, we performed RRBS on two human blood samples using 30 ng
of input DNA, and we observed a correlation of 0.96 between the two samples
(Supplementary Table 1).
Second, we optimized RRBS analysis for DNA extracted from FFPE tissue slices. Focusing
on two matched colon samples that were stored in FFPE format since 2001, we observed the
characteristic DNA degradation pattern of FFPE samples (Supplementary Fig. 1a). To avoid
degradation products in the selected size range (40–220bp), we size-selected DNA
fragments greater than 500 basepairs before digesting the genomic DNA with MspI. Our
protocol resulted in high-quality RRBS libraries (Supplementary Fig. 1b), and the
sequencing yield was comparable to fresh-frozen samples (Table 1). We also observed high
overall agreement between the FFPE samples and the fresh-frozen samples in terms of
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genomic coverage and DNA methylation measurements (Supplementary Fig. 2).
Specifically, the correlation of DNA methylation levels at CpGs with at least 25-fold
sequencing coverage was 0.87 between the fresh-frozen and the FFPE colon tumor and 0.88
between the fresh-frozen and the FFPE normal colon tissues (Supplementary Table 1).
Third, we optimized bisulfite treatment in order to maximize conversion of unmethylated
cytosines while minimizing loss of input DNA due to bisulfite-induced degradation. Across
multiple experiments in clinical samples and mouse ES cells, we found a conversion
protocol with two subsequent 5-hour bisulfite treatments10 was more effective than our
previously used single-step 14-hour protocol (conversion rate >99% in all experiments). We
also performed RRBS on in vitro methylated and in vivo demethylated DNA from a single
cell line. This experiment confirmed that the overall level of DNA methylation does not
have a visible effect on the bisulfite conversion rate (Table 1). Finally, we compared the
DNA sequence properties (sequence composition, structural features, repeat content, etc.)
between the regions that exhibited comparatively low vs. high levels of bisulfite conversion,
using the EpiGRAPH web service11. No consistent correlation with the bisulfite conversion
rates could be identified (data not shown), suggesting that systematic bisulfite conversion
bias is not a problem when applying RRBS to human disease samples.
As an additional validation, we performed DNA methylation analysis of the fresh-frozen
colon tumor sample using the Infinium HumanMethylation27 platform, which combines
bisulfite conversion with a genotyping microarray to measure DNA methylation in promoter
regions12. For 1,027 CpGs both methods yielded high-confidence measurements, and we
observed a correlation of 0.88 between Infinium and RRBS (Fig. 1c). Furthermore, when we
allowed for up to 100 basepairs distance between the CpGs assayed by Infinium and RRBS,
the high-confidence overlap between both methods increased to 7,324 CpGs, while the
correlation between the two assays remained high (Pearson’s r = 0.77). This observation is
consistent with high autocorrelation of DNA methylation levels in the CpG-rich regions of
the human genome13,14 and provides justification for measuring DNA methylation at a
subset of indicator CpGs, rather than at every single CpG within a given region.
To complement the experimental optimizations described above, we developed a
bioinformatic data analysis pipeline that is designed to identify subtle alterations of DNA
methylation in genomic regions with putative gene-regulatory potential (Supplementary
Note). This pipeline builds upon a comprehensive set of pre-annotated genomic regions
(which includes promoters, CpG islands and many other genomic features). For each region
it performs a statistical test for differential DNA methylation, and it calculates p-values
without having to introduce any arbitrary threshold parameters. Multiple-testing correction
is performed by controlling the false discovery rate. Importantly, restricting the analysis to a
relevant subset of the genome increases the statistical power for detecting subtle alterations
in gene-regulatory regions, because the p-values are not diluted by multiple-testing
correction for regions that are a priori unlikely to be differentially methylated.
To illustrate the features of the bioinformatic analysis pipeline, we compared the DNA
methylation profile of the colon tumor with matched normal colon tissue. We observed
tumor-specific hypermethylation at 52 gene promoters, 114 CpG islands and hundreds of
additional genomic regions. Affected genes include SOX17 (Fig. 1d) and GATA5
(Supplementary Fig. 3), which are known targets of hypermethylation in colon cancer15,16.
However, classical targets such as APC and MGMT were unmethylated in this particular
tumor. To corroborate the observation that the tumor exhibits hypermethylation at a
relatively small number of genes, we assessed whether or not the tumor classifies as CpG
island methylator phenotype (CIMP) based on a recently published biomarker17. CIMP is a
characteristic property of a subset of colon cancers exhibiting widespread DNA methylation
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at a large number of CpG island promoters. We inspected the promoters of five genes that
have been identified as predictive of CIMP17, and the RRBS data clearly denote the tumor
as CIMP-negative. In addition to hypermethylation at a small but significant number of gene
promoters, we also observe cases of tumor-specific hypomethylation. An example is HNF4A
(Fig. 1d), a hepatic transcription factor that has an essential role in colon development18.
The RRBS method’s deep coverage of gene promoters plus selective sampling of all other
types of genomic regions makes it most useful for detecting novel epigenetic alterations, for
example in the context of biomarker discovery19. Compared to truly genome-wide bisulfite
sequencing, its focus on a reduced representation of the genome translates into a substantial
cost advantage and the ability to screen larger patient cohorts. On the other hand, padlock-
targeted bisulfite sequencing and epigenotyping microarrays currently achieve substantially
lower genomic coverage, making these technologies more suitable for validating findings
than for initial discovery. In terms of sample quality and input DNA requirements, RRBS is
more forgiving than any other method for epigenome profiling that we are aware of. It is
thus possible to run RRBS as an add-on for essentially all ongoing tumor genomics
initiatives, and to generate genome-wide methylation profiles of some of the most
interesting and best-annotated sample collections. Finally, with ever-decreasing sequencing
costs RRBS will readily scale to more comprehensive genomic coverage, for example, by
using additional restriction enzymes or widening the size-selection window.
Online Methods
Sample origin and DNA extraction
DNA for a primary colon tumor and adjacent normal colon tissue was purchased from
BioChain (lot number A704198). Both samples came from the same donor, an 81-year-old
male patient diagnosed with moderately differentiated adenocarcinoma. In vitro methylated
and 5-aza-cytidine demethylated Jurkat genomic DNA samples were obtained from New
England Biolabs (NEB). Formalin fixed, and paraffin-embedded (FFPE) colon carcinoma
and matching normal tissue blocks were purchased from OriGene Technical Inc. These
samples were derived from an 89-year-old male patient and FFPE-processed in 2001.
Genomic DNA was isolated using a RecoverALL total nucleic acid isolation kit (Applied
Biosystems/Ambion) according to the manufacture’s recommendation. After purification,
degraded genomic DNA was size-selected on a 0.8% agarose gel. DNA fragments larger
than 500 basepairs were extracted using a QIAGEN gel purification kit. Genomic DNA
from human blood cells was extracted as described previously20. To obtain comparable,
high-quality DNA and to remove residual cellular proteins, all commercial DNA samples
were further purified using a standard phenol:chloroform:isoamyl alcohol (25:24:1)
protocol20. Mouse ES cells were cultured according to established protocols4. All cells
were grown on 0.2% gelatin for at least two passages before isolation of DNA. Mouse
genomic DNA was extracted as described previously20.
RRBS library construction
30 ng to 1 μg of human or mouse genomic DNA was digested with 5 to 20 units of MspI
(NEB) in a 20 μl reaction for 16 to 20 hours at 37 °C. Digested DNA was
phenol:chloroform:isoamyl alcohol purified as described above and DNA pellets were
resolved in 10 μl EB buffer for end-repair. Digested DNA was filled in and adenylated in a
50 μl reaction containing 10 units of Klenow fragment (3′ → 5′ exo−, NEB), 40 μM dGTP,
40 μM 5′ methylated dCTP (Roche), 400 μM dATP and 1× NEB buffer 2. The reaction was
incubated 20 min at 30 °C followed by 20 min at 37 °C. Purified adenylated DNA fragments
were ligated with pre-annealed synthetic 5-methylcytosine-containing Illumina adapters in a
50 μl reaction consisting of 2,000 cohesive end units of T4 ligase (NEB), 10 μl adenylated
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DNA and 0.5 to 1.0 μM of the adapter for 16 to 20 hours at 16 °C. Before size selection, the
adapter-ligated DNA was purified following the standard phenol:chloroform:isoamyl
alcohol protocol. Size selection was conducted as described previously20. Briefly, purified
DNA was run on a 3% NuSieve 3:1 agarose gel until the bromophenol blue within the
loading dye had run for 4 to 5 cm. To obtain 40 to 120 basepair and 120 to 220 basepair
MspI digested genomic DNA fragments, we excised adapter-ligated fragments that run at
150 to 230 basepair and 230 to 330 basepair, respectively. (Due to special characteristics of
the Illumina adapters, the lengths of the final DNA fragments are not directly additive.) To
generate the 30 ng input RRBS library, 50 ng sheared and dephosphorylated Escherichia
coli K12 genomic DNA was used as a carrier for gel size-selection and subsequent bisulfite
conversion. Size-selected DNA was bisulfite-treated using EpiTect Bisulfite Kit (Qiagen).
To validate and improve bisulfite conversion conditions of human genomic DNA, we tested
different bisulfite conversion protocols: (i) the manufacturer’s standard 5-hour conversion
protocol (99 °C for 5 min, 60 °C for 25 min, 99 °C for 5 min, 60 °C for 85 min, 99 °C for 5
min, 60 °C for 175 min); (ii) two rounds of the standard conversion10; (iii) an
approximately 14-hour phase conversion which included three additional cycles of 5 min of
denaturation at 95 °C followed by 3 h at 60 °C after the 5-hour phase standard
conversion4,20. Bisulfite-converted DNA was eluted twice from the EpiTect spin column
with 20 μl pre-heated EB buffer per elution. Analytical (10 μl) PCR reactions containing 0.5
μl of bisulfite-treated DNA, 0.2 μM each of Illumina PCR primers LPX1.1 and 2.1 and 0.5
U PfuTurbo Cx Hotstart DNA polymerase (Stratagene) were set up to determine the
minimum number of PCR cycles. Reactions were performed under the following
thermocycler conditions: 5 min at 95 °C, n × (20 s at 95 °C, 30 s at 65 °C, 30 s at 72 °C),
followed by 7 min at 72 °C, with n ranging from 12 to 18 cycles. The final libraries were
generated by large-scale amplification (8 × 25 μl) with each 25 μl aliquot containing 2 to 4
μl of bisulfite-converted template, 1.25 U PfuTurbo Cx Hotstart polymerase, and 0.2 μM
each of Illumina LPX1.1 as well as 2.1 PCR primers. PCR was performed using the same
PCR profile as in the analytical protocol. QIAquick-purified PCR products were subjected to
a final size-selection step on a 3% NuSieve 3:1 agarose gel. SYBR-green-stained gel slices
containing adaptor-ligated fragments were excised. RRBS library material was recovered
from the gel (QIAquick) and quantified by a Quant-iT (Invitrogen) assay.
Sequencing and alignment
RRBS libraries were sequenced on the Genome Analyzer II (Illumina) using the established
single-end sequencing protocol. Genomic alignment was performed as described
previously4. Briefly, two reference sequences of size-selected MspI fragments are
constructed in silico, one in which the genomic sequence is maintained as is, and one in
which all Cs are replaced by Ts (the latter reflects complete bisulfite conversion of cytosines
into thymines). During the alignment, residual Cs within each read are also converted into
Ts and aligned against the reference sequence that consists of all converted MspI fragments.
The alignment itself uses a straightforward seed-and-extension algorithm, which identifies
all perfect 12 bp alignments and extends without gaps from either end of the established
seed. Mismatches are counted and used as a quality measure. However, C-to-T conversions
between the genomic DNA sequence and the read are not counted as mismatches but
marked for downstream methylation calling. The best alignment is kept only in cases where
the second-best alignment has at least three more mismatches, while reads that do not meet
this stringency criterion are discarded. Bisulfite conversion rates are calculated as the
number of genomic cytosines outside a CpG context that are unconverted, divided by the
total number of cytosines outside a CpG context.
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Bioinformatic analysis
Disease-specific epigenetic alterations are typically more subtle than tissue-specific
differences and changes related to cell differentiation, to which RRBS was originally
applied4. We therefore developed a bioinformatic pipeline that scores epigenetic alterations
according to strength and significance, and links them to potentially affected genes. To that
end, we collected a comprehensive set of regions of interest, which includes promoters, CpG
islands, CpG island shores, enhancers, exons, introns, and repetitive elements. For each of
these regions, the number of methylated and unmethylated CpG observations is determined,
and a p-value is assigned using Fisher’s exact test. Once all p-values are calculated,
multiple-testing correction is performed separately for each region type using the q-value
method21, which controls the false discovery rate to be below a user-specified threshold
(typically 10%). A simple power calculation shows that – for a given candidate region with
coverage of 50 individual CpG measurements (Fig. 1a) – the power to detect a difference of
0% methylation vs. 20% methylation is 95% (significance level of 0.05). The software
pipeline is implemented in Python (alignment processing module) and R (statistical analysis
module). The source code package with documentation and demonstration data is available
online (Supplementary Note). Future updates will be posted on
http://rrbs-techdev.computational-epigenetics.org.
Supplementary website
Using the software described in the previous section, we generated a comprehensive analysis
of the RRBS experiments described in this paper. The supplementary website hosts all
relevant results, including genome browser tracks visualizing the raw DNA methylation
data; coverage statistics, mean methylation boxplots and clustering diagrams that provide an
initial overview; and scatterplots, pairwise correlations as well as statistical significance
calls that facilitate in-depth analysis. The supplementary website is available from the
following URL: http://rrbs-techdev.computational-epigenetics.org.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank K. Halachev (Max Planck Institute for Informatics) for the provision of genome annotation files and H.
Cedar (The Hebrew University of Jerusalem) for providing the human blood DNA samples. C. Bock is supported
by a Feodor Lynen Fellowship from the Alexander von Humboldt Foundation. A. Meissner is supported by the
Massachusetts Life Science Foundation and the Pew Charitable Trusts. The described work was in part funded by
NIH grants R01HG004401, U54HG03067 and U01ES017155.
References
1. Esteller M. Nat Rev Genet 2007;8:286–298. [PubMed: 17339880]
2. Lister R, Ecker JR. Genome Res 2009;19:959–966. [PubMed: 19273618]
3. Meissner A, Gnirke A, Bell GW, et al. Nucleic Acids Res 2005;33:5868–5877. [PubMed:
16224102]
4. Meissner A, Mikkelsen TS, Gu H, et al. Nature 2008;454:766–770. [PubMed: 18600261]
5. Down TA, Rakyan VK, Turner DJ, et al. Nat Biotechnol 2008;26:779–785. [PubMed: 18612301]
6. Serre D, Lee BH, Ting AH. Nucleic Acids Res. 2009 published online November 11.
7. Brunner AL, Johnson DS, Kim SW, et al. Genome Res 2009;19:1044–1156. [PubMed: 19273619]
8. Irizarry RA, Ladd-Acosta C, Carvalho B, et al. Genome Res 2008;18:780–790. [PubMed:
18316654]
9. Irizarry RA, Ladd-Acosta C, Wen B, et al. Nat Genet 2009;41:178–186. [PubMed: 19151715]
Gu et al. Page 6
Nat Methods. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
10. Lister R, O’Malley RC, Tonti-Filippini J, et al. Cell 2008;133:523–536. [PubMed: 18423832]
11. Bock C, Halachev K, Büch J, et al. Genome Biol 2009;10:R14. [PubMed: 19208250]
12. Bibikova M, Le J, Barnes B, et al. Epigenomics 2009;1:177.
13. Bock C, Walter J, Paulsen M, et al. Nucleic Acids Res 2008;36:e55- . [PubMed: 18413340]
14. Eckhardt F, Lewin J, Cortese R, et al. Nat Genet 2006;38:1378–1385. [PubMed: 17072317]
15. Hellebrekers DM, Lentjes MH, van den Bosch SM, et al. Clin Cancer Res 2009;15:3990–3997.
[PubMed: 19509152]
16. Zhang W, Glockner SC, Guo M, et al. Cancer Res 2008;68:2764–2772. [PubMed: 18413743]
17. Weisenberger DJ, Siegmund KD, Campan M, et al. Nat Genet 2006;38:787–793. [PubMed:
16804544]
18. Garrison WD, Battle MA, Yang C, et al. Gastroenterology 2006;130:1207–1220. [PubMed:
16618389]
19. Bock C. Epigenomics 2009;1:99.
20. Smith ZD, Gu H, Bock C, et al. Methods. 2009
21. Storey JD, Tibshirani R. Proc Natl Acad Sci U S A 2003;100:9440–9445. [PubMed: 12883005]
Gu et al. Page 7
Nat Methods. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Optimizing bisulfite sequencing for genome-scale profiling of human disease samples
(a) Typical RRBS coverage of gene promoters (2-kilobase regions centered on RefSeq-
annotated transcription start sites), CpG islands (annotated with a stringent version of the
Gardiner-Garden criteria, requiring a minimum length of 700 basepairs) and putative
regulatory elements (mapped by DNase hypersensitivity). All data are for colon tumor, run
no. 1 in Table 1. The values refer to the number of individual CpG measurements in the
region that pass quality control. Correlation between (b) RRBS performed on 30 ng and 100
ng of input DNA derived from mouse ES cells and (c) DNA methylation measurements for
colon tumor, obtained by RRBS and Infinium, at 1,027 high confidence CpGs (RRBS:
sequencing coverage ≥ 20, Infinium: detection p-value < 0.05). (d) Distribution of DNA
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methylation in the promoter regions of SOX17 (hypermethylated in the colon tumor) and
HNF4A (hypomethylated). Unmethylated reads are shown in red, partially methylated reads
in grey and methylated reads in blue.
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